Seven trials assessed the effectiveness of ICIs in NSCLC patients who were wild-type or had an EGFR mutation (three with hazard rate of OS and three with hazard rate of PFS) [20–26]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.